Beam Therapeutics P/E
What is the P/E of Beam Therapeutics?
The P/E of Beam Therapeutics Inc. is N/A
What is the definition of P/E?
Price to earnings ratio is the ratio of a company’s stock price to the company’s earnings per share calculated over trailing twelve months.
= previous day’s close / ttm EPS
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E of companies in the Health Care sector on NASDAQ compared to Beam Therapeutics
What does Beam Therapeutics do?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Companies with p/e similar to Beam Therapeutics
- Glittek Granites has P/E of N/A
- Nanalysis Scientific has P/E of N/A
- Shuanghua has P/E of N/A
- Blue Rhino Capital has P/E of N/A
- Angus Ventures Inc has P/E of N/A
- Dynamo Capital has P/E of N/A
- Beam Therapeutics has P/E of N/A
- China Singyes New Materials has P/E of N/A
- Fusion Gold has P/E of N/A
- DigitalX has P/E of N/A
- Genfit SA has P/E of N/A
- Deltic Plc has P/E of N/A
- Zephyr Minerals has P/E of N/A